Biotechnology is a high-risk, high-reward landscape where innovation determines success. Yet, occasionally, a small player ...

Invivyd (IVVD) announced a strategic partnership with professional football coach Jim Harbaugh to raise awareness about the ongoing short and ...

Teaming up to raise awareness of the continuing toll of COVID-19 in America, an ongoing mass disabling event causing an American death approximately every 9 minutes with over 59,0 ...

Invivyd, Inc. is a microcap biotech company focusing on antibody-based treatments for infectious diseases like COVID-19.

H.C. Wainwright reaffirmed its Buy rating and $10.00 price target for Invivyd Inc. (NASDAQ:IVVD), following a series of positive developments for the biotechnology company. The stock, currently ...

The stock is trading at 1.0150, up 0.6573, gaining 183.7573% on volume of over 422 Million shares, with a day's high of $1.11. The stock announced breaking news on its Monoclonal Antibody designed to ...

We recently compiled a list of the Why These 15 Healthcare Stocks Are Skyrocketing So Far In 2025. In this article, we are ...

Invivyd data shows strong potency and prolonged antibody levels in trials. Q4 Pemgarda revenue rose 48% to $13.8 million.

Invivyd (IVVD) announced positive data from its ongoing Phase 1/2 clinical trial of VYD2311, Invivyd’s novel monoclonal antibody candidate ...